SCYNEXIS to Participate in Upcoming Investor Conferences

Rhea-AI Summary

SCYNEXIS, a biotechnology company focused on innovative treatments for drug-resistant infections, will participate in two upcoming virtual investor conferences in September 2021. The conferences include the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, featuring an on-demand presentation and one-on-one meetings, and the Cantor Fitzgerald Virtual Global Healthcare Conference on September 30, with a live presentation. More information and archived webcasts will be available on their website for 30 days post-event.

JERSEY CITY, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the Company will participate in the following virtual investor conferences in September.

Presentation details can be found below:

• H.C. Wainwright 23^rd Annual Global Investment Conference
  Format: On demand presentation and 1-on-1 meetings
  Date and Time: Presentation available Monday, September 13 at 7 am ET, 1-on-1 meetings September 13-15
  Registration Link

• Cantor Fitzgerald Virtual Global Healthcare Conference
  Format: Live presentation and 1-on-1 meetings
  Date and Time: Thursday, September 30 from 2:40-3:10 pm ET (Track 2)

The presentations and archived webcasts can be found on the SCYNEXIS website at: https://www.scynexis.com/news-media/events for 30 days following the event.

About SCYNEXIS
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS scientists are developing the company’s lead asset, ibrexafungerp (formerly known as SCY-078), as a broad-spectrum, systemic antifungal for multiple fungal indications in both the community and hospital settings. SCYNEXIS has initiated the launch of its first commercial product in the U.S., BREXAFEMME^® (ibrexafungerp tablets), which was approved by the U.S. Food and Drug Administration (FDA) on June 1, 2021. In addition, late-stage clinical investigation of ibrexafungerp for the prevention of recurrent vulvovaginal candidiasis (rVVC) and the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing. For more information, visit www.scynexis.com. 

CONTACT: 
Investor Relations
Irina Koffler
LifeSci Advisors
Tel: (646) 970-4681
ikoffler@lifesciadvisors.com

Media Relations
Gloria Gasaatura
LifeSci Communications
Tel: (646) 970-4688
ggasaatura@lifescicomms.com

FAQ

What investor conferences will SCYNEXIS participate in September 2021?

SCYNEXIS will participate in the H.C. Wainwright 23rd Annual Global Investment Conference on September 13 and the Cantor Fitzgerald Virtual Global Healthcare Conference on September 30.

When is the H.C. Wainwright Conference presentation scheduled for SCYNEXIS?

The H.C. Wainwright presentation for SCYNEXIS will be available on September 13 at 7 am ET.

What is the format of the Cantor Fitzgerald Conference for SCYNEXIS?

The Cantor Fitzgerald Conference for SCYNEXIS will feature a live presentation and one-on-one meetings on September 30.

Where can I find the presentations from SCYNEXIS's conferences?

Presentations and archived webcasts from SCYNEXIS's conferences will be available on their website for 30 days following the events.

What is the ticker symbol for SCYNEXIS?

The ticker symbol for SCYNEXIS is SCYX.